Published 21 August 2009, doi:10.1136/bmj.b3276
Cite this as: BMJ 2009;339:b3276

Analysis

Economics of biological therapies

¹ University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge CB2 0QQ, ² Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s Hospital

Demand for biological drugs is putting pressure on health budgets. Christopher Kelly and Fraz Mir examine why they are so expensive and what can be done to increase access

The first 150 words of the full text of this article appear below.

The success of biopharmaceuticals is producing a growing problem for public healthcare services worldwide. Newer biological therapies offer fresh hope for the treatment of many serious diseases but are much more expensive than conventional drugs. Clinicians are increasingly finding themselves torn between offering new treatments to patients and respecting the financial restrictions imposed by healthcare authorities on the basis of cost effectiveness.

In the UK, the NHS has been under pressure after the National Institute for Health and Clinical Excellence (NICE) initially recommended against funding drugs such as trastuzumab for breast cancer, erlotinib for non-small cell lung cancer, and ranibizumab for age related wet macular degeneration.¹ Widespread emotive media coverage of such cases heightens public expectation that the health service will fund all drugs in all situations, regardless of cost. However, unless biological therapies can be made more affordable, Western healthcare systems face a financial crisis, exacerbated by the pressures . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

NICE and the challenge of cancer drugs

James Raftery
BMJ 2009 338: b67. [Extract] [Full Text]

Value based pricing for NHS drugs: an opportunity not to be missed?

Karl Claxton, Andrew Briggs, Martin J Buxton, Anthony J Culyer, Christopher McCabe, Simon Walker, and Mark J Sculpher
BMJ 2008 336: 251-254. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

The main strength of the value-based approach for drug pricing

Andrea Messori
bmj.com, 25 Aug 2009 [Full text]

Biosimilars are not biosame

Dyfrig A Hughes, et al.
bmj.com, 1 Sep 2009 [Full text]

Online poll

Find out more here>> and here>>